NON-HODGKINS LYMPHOMA
Clinical trials for NON-HODGKINS LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKINS LYMPHOMA trials appear
Sign up with your email to follow new studies for NON-HODGKINS LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of three drugs (glofitamab, atezolizumab or polatuzumab vedotin, plus a pre-treatment of obinutuzumab) in adults with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. The goal is to find the safest dose and see if…
Matched conditions: NON-HODGKINS LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New lymphoma cocktail shows promise in early japanese trial
Disease control OngoingThis study tests the safety and effectiveness of a drug called tafasitamab, given alone or combined with other medicines (lenalidomide, parsaclisib, or R-CHOP), in Japanese adults with Non-Hodgkin lymphoma. About 72 participants with relapsed or untreated disease will receive dif…
Matched conditions: NON-HODGKINS LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Incyte Biosciences Japan GK • Aim: Disease control
Last updated May 06, 2026 16:01 UTC